Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Therefore, butyrate has become an attractive drug target for T2D, and treatment strategies have been devised to increase its intestinal levels, for example by supplementation of butyrate-producing bacteria and dietary fiber, or through fecal microbiota transplant (FMT)
Clinical studies have generally shown good tolerance at recommended doses, with most adverse effects being mild and transient
In conclusion, we have shown that GSTO1 is a novel and exciting target for developing anticancer and anti-inflammatory agents
Concurrent use may potentiate or antagonize the effects of lidocaine, leading to increased or decreased efficacy or adverse reactions
US$ 20.61
US$ 28.69
US$ 26.47
US$ 23.95
US$ 20.56
US$ 23.54
